🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Merck symposium #ESMOAsia2022 Perfect world cup line up with Japan, Australia, England and Spain represented - final 16! Lisa Pickering Enrique Grande and Prof Eto

Hey #MedTwitter Here are the basics of survival curve and hazard ratio interpretation. Trust me it's conceptually easy. Dreaded terminology will be decoded. Ever wondered what a hazard ratio really means? What is a survival function? What is cox proportional hazards? 🧵

We need more people to help run clinical trials ⁦Howard Gurney⁩ smh.com.au/business/workp…

We need comprehensive training schemes for trial coordinators and move beyond the current apprentice scheme. Experienced trial coordinators are in short supply and we need to stop poaching each others

Getting #clinicaltrials going in Dubbo and remote NSW! Florian Honeyball Nicola Chapman MQ University Clinical Trials Unit NSW Health Western NSW Health Research Network (WHRN) Inc Kylie Gwynne

Now for something completely different. My next publication! If you like murder have a read. This is the fourth in a series. #murder #mystery #fiction amazon.com/Murder-Mist-Ch…

Probably the most important take-home slide from this afternoon's session by David Braun (since I happen to agree with it!). #ASCO23 #RCC

#Ipatasertib plus #rucaparib has a manageable safety profile but did not show synergistic or additive antitumor activity in previously treated patients with #mCRPC. Jorge D Gallo Howard Gurney bit.ly/3JVSaEx

Job Opportunity: MQ Health seeks a Medical Oncology Fellow - Clinical Trials Unit. Full-time. Location: Sydney. Applications Close 26 July. More info: moga.org.au/oncology-posit…

Come and work with us at the Macquarie University trials unit MQ University Clinical Trials Unit Lots of trials, especially in GU, breast and phase 1. Part-time also considered. Dhanusha Sabanathan Dr Andrew Parsonson Alison Zhang M Crumbaker

Congratulations to Alex Flynn, winner of this year's Best New Concept - Randomised Phase III trial of personalised vs standard dosing of 5-fluorouracil in first line chemotherapy for metastatic colorectal cancer. Congrats also to our Runners-up, Andrew Dean & Tim Price #AGITG23

Well done Alex! We need more studies on dose Individualisation of cancer drugs. Stephen Ackland #PREDICT consortium. Jennifer Martin - Physician and Board Director

Thanks to all patients, families, clinicians, ANZUP, #BaCT and Bristol Myers Squibb for their support of the #UNISON #clinicaltrial now published in BJU International. Grateful for support as we tested sequential immunotherapy for people with rare variant non-clear cell #kidneycancer

#GETUG-AFU 18 trial. Better PFS, OS for high risk, node neg PC for 80 vs 70 Gy XRT + 3yr ADT. #ASCOGU Christophe Hennequin

Thanks for the opportunity to present these data on UroToday.com Link to manuscript and Tweetorial - x.com/azadoncology/s… eBioMedicine – The Lancet Discovery Science Peter Mac Cancer Centre Predicine, Inc.

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:

And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ESMO24 Dr. Fred Saad silke gillessen

#UpFrontPSMA 🧬 Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute interviews Arun Azad Peter Mac Cancer Centre on the #UpFrontPSMA study, showing the benefit of adding lutetium-PSMA-617 to docetaxel in #mHSPC! The Phase II trial revealed improved undetectable PSA rates at 48 weeks. Could lutetium-PSMA shape

Grateful for the opportunity to present DB-1311/BNT324 (a novel B7H3 ADC) a Ph 1/2 study in patients with heavily pretreated CRPC (Abstract #5015) at #ASCO25 🎤 Macquarie University investigators: John Park Dhanusha Sabanathan Howard Gurney Alison Zhang Wei Yen Chan 🧵 1/7